immatics biotechnologies GmbH
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. immatics biotechnologies GmbH's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 69% to $53,997,000. Profit margin reached -180%. Total operating expenses were $155,722,000.

Profit Margin

immatics biotechnologies GmbH (NASDAQ:IMTXW): Profit margin
2018 3.77M -31.44M -834.06%
2019 18.44M -31.74M -172.05%
2020 31.25M -229.34M -733.84%
2021 34.76M -95.06M -273.45%
2022 172.83M 37.51M 21.71%
2023 53.99M -96.99M -179.63%

IMTXW Income Statement (2018 – 2023)

2023 2022 2021 2020 2019 2018
Revenue
Revenue
53.99M172.83M34.76M31.25M18.44M3.77M
Cost of revenue
118.66M106.77M87.57M67.08M40.09M0
Gross profit
-64.66M66.05M-52.81M-35.83M-21.64M3.77M
Operating exp.
Research and development
118.66M106.77M87.57M67.08M40.09M33.97M
Selling and marketing
000000
Total operating expenses
155.72M142.87M121.05M100.96M51.46M38.17M
Operating income
-101.72M29.95M-86.29M-69.71M-33.01M-34.40M
Other income (expenses), net
4.73M12.08M-7.04M-142.12M526K1.56M
Income before tax
-96.99M42.03M-93.33M-229.61M-32.48M-32.35M
Income tax expense
04.55M1.72M-268K-746K-2.96M
Net income
-96.99M37.51M-95.06M-229.34M-31.74M-31.44M
Earnings per share
Basic EPS
-1.20.55-1.51-4.78-0.5-0.5
Diluted EPS
-1.20.54-1.51-4.78-0.5-0.5
Data sourceData sourceData sourceData source